Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting

被引：0
|
作者：
Takehara, T. [1 ]
Kato, N. [2 ]
Aikata, H. [3 ]
Kuzuya, T. [4 ]
Hiasa, Y. [5 ]
Nakamura, S. [6 ]
Yamamoto, K. [7 ]
Morimoto, N. [8 ]
Sakamori, R. [9 ]
Kawamura, Y. [10 ]
Tsuchiya, K. [11 ]
Ueshima, K. [12 ]
Hiraoka, A. [13 ]
Nakano, M. [14 ]
Kokudo, N. [15 ]
Furuse, J. [16 ]
Moriguchi, M. [17 ]
Yamashita, T. [18 ]
Ikeda, M. [19 ]
Kudo, M. [12 ]
机构：
[1] Osaka Univ, Grad Sch Med, Gastroenterol & Hepatol, Osaka, Japan
[2] Chiba Univ, Sch Med, Gastroenterol, Chiba, Japan
[3] Hiroshima Prefectural Hosp, Gastroenterol, Hiroshima, Japan
[4] Fujita Hlth Univ, Dept Gastroenterol & Hepatol, Toyoake, Aichi, Japan
[5] Ehime Univ, Grad Sch Med, Gastroenterol & Metabol, Matsuyama, Ehime, Japan
[6] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Hyogo, Japan
[7] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan
[8] Jichi Med Univ Hosp, Dept Gastroenterol, Shimotsuke, Tochigi, Japan
[9] Natl Hosp Org Osaka Natl Hosp, Gastroenterol & Hepatol, Osaka, Japan
[10] Toranomon Gen Hosp, Hepatol, Tokyo, Japan
[11] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan
[12] Kindai Univ, Fac Med, Gastroenterol & Hepatol, Osaka, Japan
[13] Ehime Prefectural Cent Hosp, Gastroenterol, Matsuyama, Ehime, Japan
[14] Kurume Univ, Sch Med, Dept Med, Div Gastroenterol, Fukuoka, Japan
[15] NCGM Natl Ctr Global Hlth & Med, Surg, Tokyo, Japan
[16] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan
[17] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan
[18] Kanazawa Univ Hosp, Gastroenterol Dept, Kanazawa, Ishikawa, Japan
[19] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.221
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
200P
引用
收藏
页码：S1480 / S1481
页数：2
相关论文
共 50 条
  • [41] A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J.
    Lieu, C.
    Raghav, K. P. S.
    Argiles, G.
    Cubillo, A.
    Qu, X.
    Yan, Y.
    Merchant, M.
    Zeuner, H.
    Gallo, J. D.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice
    Nakagawa, Miyuki
    Inoue, Masanori
    Ogasawara, Sadahisa
    Maruta, Susumu
    Okubo, Tomomi
    Itokawa, Norio
    Iino, Yotaro
    Obu, Masamichi
    Haga, Yuki
    Seki, Atsuyoshi
    Kikuchi, Yasuharu
    Kogure, Tadayoshi
    Yumita, Sae
    Ishino, Takamasa
    Ogawa, Keita
    Fujiwara, Kisako
    Iwanaga, Terunao
    Fujita, Naoto
    Sakuma, Takafumi
    Kojima, Ryuta
    Kanzaki, Hiroaki
    Koroki, Keisuke
    Taida, Takashi
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Itobayashi, Ei
    Atsukawa, Masanori
    Koma, Yoshihiro
    Azemoto, Ryosaku
    Ito, Kenji
    Mizumoto, Hideaki
    Shinozaki, Masami
    Kato, Jun
    Kato, Naoya
    CANCER, 2023, 129 (04) : 590 - 599
  • [43] First line atezolizumab plus bevacizumab (atezo/bev) or durvalumab ± tremelimumab (durva±treme) in unresectable hepatocellular carcinoma (HCC): A real world, multi-institutional retrospective cohort study.
    Kournoutas, Paulina S.
    Marell, Paulina S.
    Peersen, Anina
    Gupta, Garima
    Akce, Mehmet
    Yang, Ju Dong
    Chen, Pin-Jung
    Naleid, Nikolas
    Mahipal, Amit
    Sahai, Vaibhav
    Thompson, Scott
    Jin, Zhaohui
    Venkatesh, Sudhakar
    Borad, Mitesh J.
    Babiker, Hani M.
    Bekaii-Saab, Tanios S.
    Mcwilliams, Robert R.
    Halfdanarson, Thorvardur Ragnar
    Ou, Fang-Shu
    Tran, Nguyen H.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 532 - 532
  • [44] Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
    Meng, Lingzhan
    Li, Hu
    Ji, Yingjie
    Yu, Peng
    Wang, Zizheng
    Cao, Li
    Shi, Bin
    Shao, Yanling
    Yan, Jin
    Gao, Yinjie
    Zhu, Zhenyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
  • [45] EXPLORATORY EFFECTIVENESS OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA ( HCC) BEYOND RADIOLOGICAL PROGRESSION: A REAL- WORLD, MULTICENTER COHORT STUDY
    Tabuchi, Takaya
    Taniki, Nobuhito
    Kasuga, Ryosuke
    Chu, Po-sung
    Nakadai, Yukie
    Kondo, Mayuko
    Noguchi, Fumie
    Morikawa, Rei
    Shiba, Shunsuke
    Tahara, Toshiyuki
    Komatsu, Hirokazu
    Fujita, Yuriko
    Kaneko, Fumihiko
    Hoshi, Hitomi
    Ojiro, Keisuke
    Hosoda, Yasuo
    Yamaguchi, Akihiro
    Fukuhara, Seiichiro
    Okamura, Yukishige
    Kanamori, Hideaki
    Kanai, Takanori
    Nakamoto, Nobuhiro
    HEPATOLOGY, 2023, 78 : S1841 - S1842
  • [46] COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
    Boonkaya, Sangdao
    Thanapirom, Kessarin
    Siripon, Nipaporn
    Thaimai, Panarat
    Ananchuensook, Prooksa
    Sriphoosanaphan, Supachaya
    Tanasanvimon, Surbpong
    Treeprasertsuk, Sombat
    Komolmit, Piyawat
    GASTROENTEROLOGY, 2024, 166 (05) : S73 - S74
  • [47] The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study
    Wang, Xishu
    Sun, Ximin
    Lei, Yongrong
    Fang, Lingyan
    Wang, Yuedi
    Feng, Kai
    Xia, Feng
    BMC CANCER, 2024, 24 (01)
  • [48] Safety and efficacy of atezolizumab and bevacizumab delivered through a hepatology clinic for patients with unresectable hepatocellular carcinoma: Results from an Australian real-world study
    Kurup, R.
    Subhaharan, D.
    Gaggin, B.
    Wickremeratne, T.
    Sloss, A.
    Mitchell, J.
    Gupta, R.
    O'Beirne, J.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 77 - 77
  • [49] A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe
    Rossari, F.
    Tada, T.
    Shimose, S.
    Kudo, M.
    Yoo, C.
    Cheon, J.
    Finkelmeier, F.
    Lim, H. Y.
    Presa, J.
    Masi, G.
    Bergamo, F.
    Amadeo, E.
    Vitiello, F.
    Foti, S.
    Camera, S.
    Persano, M.
    Stefanini, B.
    Scartozzi, M.
    Rimini, M.
    Gardini, A. Casadei
    ANNALS OF ONCOLOGY, 2024, 35 : S82 - S82
  • [50] Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
    D'Alessio, Antonio
    Weinmann, Arndt
    Galle, Peter
    Gaillard, Vincent
    Fulgenzi, Claudia Angela Maria
    Bettinger, Dominik
    Bengsch, Bertram
    Vogel, Arndt
    Balcar, Lorenz
    Scheiner, Bernhard
    Amara, Suneetha
    Muzaffar, Mahvish
    Naqash, Abdul Rafeh
    Personeni, Nicola
    Pressiani, Tiziana
    Sharma, Rohini
    Pinter, Matthias
    Cortellini, Alessio
    Rimassa, Lorenza
    Pinato, David J.
    JOURNAL OF HEPATOLOGY, 2022, 77 : S376 - S376
12345